SynthesisJournal of gastrointestinal cancer2026
Safety and Efficacy of Triple Therapy Containing Encorafenib, Cetuximab, and Binimetinib for BRAF V600E-Mutated Colorectal Cancer: a Systematic Review and Meta-Analysis.
Synthesis in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBRAF V600E-mutated colorectal cancer (CRC) is associated with poor prognosis and resistance to standard chemotherapy. Emerging evidence, including the BEACON trial and subsequent real-world studies, suggests that triple therapy targeting BRAF oncoprotein, epidermal growth factor receptor (EGFR), and MEK improves clinical outcomes.
objectiveTo evaluate the survival, treatment response, and safety outcomes associated with triple therapy comprising encorafenib, cetuximab, and binimetinib in patients with BRAF V600E-mutated CRC.
methodsA systematic review and meta-analysis were conducted in accordance with the PRISMA guidelines. A comprehensive search of PubMed, Cochrane Central, and ClinicalTrials.gov was performed until October 2024. Proportional outcomes were pooled using inverse-variance logit-transformed random-effects models, and time-to-event outcomes were synthesized using a random-effects survival meta-analysis. Hetrogenity was quantified using I ² statistics. Primary outcomes included overall survival (OS), progression-free survival (PFS), and objective response rate (ORR), while secondary outcomes focused on safety and adverse events.
resultsSix studies (one randomized trial, one phase II trial, and four cohort studies) involving 487 patients were included. The pooled 12-month OS rate was 44% (95% CI: 29-66%), with a median OS of 9.75 months (95% CI: 7.22-15.69). The 12-month PFS rate was 13% (95% CI, 7-24%), and the median PFS was 4.89 months (95% CI: 4.22-6.46). The ORR was 35% (95% CI: 27-44%), including a 5% complete response rate and a 32% partial response rate. Grade ≥ 3 adverse events occurred in 46% of the patients, most commonly acneiform dermatitis and diarrhea.
conclusionTriple therapy with encorafenib, cetuximab, and binimetinib offers meaningful improvements in survival and tumor response in BRAF V600E-mutated CRC, although the toxicity remains substantial. Optimizing patient selection and managing adverse events are critical for broader clinical use.
Indexed as
Identifiers
41677963What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.